Rejuveinix is under clinical development by Reven and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) Pneumonia have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rejuveinix’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rejuveinix overview
Rejuveinix is under development for the treatment of critical limb ischemia, peripheral arterial disease, endothelial dysfunction, COVID-19 related acute respiratory distress syndrome, hypoxemic respiratory failure, covid-19 pneumonia and sepsis. It is administered through intravenous route. It was also developed for acute ischemic stroke and coronary artery disease.
Reven overview
Reven (Reven Pharmaceuticals) is a biopharmaceutical company. It is in the research and development of products for cardiovascular diseases. The company develops Rejuveinix (RJX) technology, an intravenous (IV) drug technology platform, which offers support to cells. The RJX platform technology is into metabolic function areas, that provide circulatory relief to patients who are suffering from peripheral arterial disease and other vascular-related medical conditions. The company also concentrates on developing products for endovascular health, especially for improved perfusion, endothelial function, oxygenation, and metabolism areas. Reven is headquartered in Golden, Colorado, the US.
For a complete picture of Rejuveinix’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
